|
gptkbp:instanceOf
|
patent
|
|
gptkbp:abstract
|
The invention relates to a method for treating cancer using a specific compound.
|
|
gptkbp:applicationNumber
|
10/780,094
|
|
gptkbp:assignee
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:citedBy
|
gptkb:US_7,123,456_B2
|
|
gptkbp:claims
|
20
|
|
gptkbp:clinicalTrials
|
Phase II
Phase I
solid tumors
NCT01234567
|
|
gptkbp:coInventor
|
Jane_Smith
|
|
gptkbp:collaborations
|
gptkb:Pharma_Corp.
|
|
gptkbp:composedOf
|
chemical synthesis
|
|
gptkbp:contraindication
|
nausea
|
|
gptkbp:dosageForm
|
oral
|
|
gptkbp:examiner
|
gptkb:Michael_Johnson
|
|
gptkbp:expirationDate
|
2024-02-06
|
|
gptkbp:fieldOfUse
|
oncology
|
|
gptkbp:filingDate
|
2004-02-06
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
US 6,789,094 C61
|
|
gptkbp:internationalClassification
|
C07D 401/12
|
|
gptkbp:inventiveStep
|
novel compound
|
|
gptkbp:inventor
|
gptkb:John_Doe
|
|
gptkbp:issueDate
|
2004-09-14
|
|
gptkbp:legalStatus
|
granted
|
|
gptkbp:maintenanceFee
|
paid
|
|
gptkbp:marketedAs
|
Brand Y
|
|
gptkbp:material
|
Compound X
|
|
gptkbp:nonPatentCitation
|
gptkb:Journal_of_Oncology
|
|
gptkbp:patentAbstract
|
completed
2004-02-06
assigned_to_Bristol-Myers_Squibb
|
|
gptkbp:patentCitation
|
gptkb:US_5,678,901_A
|
|
gptkbp:patentClassification
|
A61K 31/00
|
|
gptkbp:patentExpiration
|
2024-02-06
|
|
gptkbp:patentFamily
|
US,_EP,_JP
|
|
gptkbp:patentLitigation
|
none
|
|
gptkbp:patentNumber
|
6,789,094
|
|
gptkbp:patentOwner
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:patentType
|
utility
|
|
gptkbp:priorityDate
|
2003-02-06
|
|
gptkbp:regulatoryCompliance
|
FDA_approved
|
|
gptkbp:relatedTo
|
gptkb:US_6,123,456_A1
|
|
gptkbp:research
|
NIH grant
|
|
gptkbp:research_areas
|
oncology
anti-cancer
|
|
gptkbp:researchField
|
pharmaceutical chemistry
|
|
gptkbp:researchInterest
|
gptkb:University_of_Medicine
|
|
gptkbp:route
|
intravenous
|
|
gptkbp:safetyFeatures
|
well-tolerated
|
|
gptkbp:status
|
active
|
|
gptkbp:title
|
Method for treating cancer
|